M. Rettig

F. Gao, R. Vij, P. Westervelt, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

First-in-Humans Evaluation of Safety and Dosimetry of 64Cu-LLP2A for PET Imaging

S. Achilefu, R. Vij, J. Dipersio, 2022, The Journal of Nuclear Medicine.

Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.

F. Gao, F. Gao, J. Dipersio, 2016, Blood.

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

R. Vij, P. Westervelt, J. Dipersio, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Protein kinase C activation induces phosphatidylserine exposure on red blood cells.

P. Low, F. Kuypers, K. de Jong, 2002, Biochemistry.

Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis.

P. Low, C. Hillery, P. Gallagher, 2003, Blood.

A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes

R. Vij, S. Kulkarni, K. Trinkaus, 2021, Leukemia & lymphoma.

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia

M. Konopleva, M. Andreeff, P. Westervelt, 2017, Blood Cancer Journal.

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.

R. Vij, S. Kulkarni, K. Trinkaus, 2012, Blood.

Bone Marrow Stromal Cells Modulate Mouse ENT1 Activity and Protect Leukemia Cells from Cytarabine Induced Apoptosis

J. Dipersio, P. Ramírez, B. Nervi, 2012, PloS one.

Enhanced in utero allogeneic engraftment in mice after mobilizing fetal HSCs by α4β1/7 inhibition.

J. Dipersio, A. Flake, W. Peranteau, 2016, Blood.

Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis.

J. Dipersio, Julie K. Ritchey, A. Ghobadi, 2014, Blood.

plerixafor in relapsed or refractory acute myeloid leukemia A phase I/II study of chemosensitization with the CXCR4 antagonist

S. Kulkarni, K. Trinkaus, P. Westervelt, 2012 .

A phase 1 / 2 study of chemosensitization with the CXCR 4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

R. Vij, S. Kulkarni, K. Trinkaus, 2012 .

Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR 4 antagonists in mice

J. Dipersio, S. Pitson, L. Bendall, 2012 .

Suicide genes: monitoring cells in patients with a safety switch

J. Dipersio, D. Piwnica-Worms, F. Dehdashti, 2014, Front. Pharmacol..

using plerixafor, an antagonist of the CXCR4/SDF-1 interaction Rapid mobilization of functional donor hematopoietic cells without G-CSF

R. Vij, P. Westervelt, D. Link, 2011 .

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.

R. Vij, P. Westervelt, D. Link, 2008, Blood.

Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.

J. Dipersio, M. Rettig, M. Christopher, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MYELOID NEOPLASIA Targeting CD 123 in acute myeloid leukemia using a T-cell – directed dual-af fi nity retargeting platform

F. Gao, F. Gao, J. Dipersio, 2015 .

TRANSPLANTATION Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells

J. Dipersio, E. Chendamarai, S. Millard, 2017 .

Kinetics of In Vivo Elimination of Suicide Gene-Expressing T Cells Affects Engraftment, Graft-versus-Host Disease, and Graft-versus-Leukemia after Allogeneic Bone Marrow Transplantation1

J. Haug, J. Dipersio, D. Piwnica-Worms, 2004, The Journal of Immunology.

Inhibition Of Nuclear Transport Modulator Xpo1/CRM1 For The Treatment Of Acute Myeloid Leukemia (AML)

J. Dipersio, J. Prior, S. Shacham, 2013 .

Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury

J. Dipersio, N. Stitziel, M. Scherrer-Crosbie, 2021, bioRxiv.

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

B. Fox, J. Dipersio, J. Wigginton, 2017 .

Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells

G. Uy, A. Cashen, M. Rettig, 2008 .

Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.

J. Dipersio, Julie K. Ritchey, S. Persaud, 2021, The Journal of clinical investigation.

NIH SenNet Consortium to map senescent cells throughout the human lifespan to understand physiological health.

Philip D. Blood, Ellen M. Quardokus, Matthew A. Wyczalkowski, 2022, Nature aging.

396 NT-I7, a long-acting interleukin-7, promotes expansion of CD8 T cells and NK cells and immune activation in patients with newly diagnosed high-grade gliomas after chemoradiation

Omar H. Butt, N. Le, G. Dunn, 2021, Journal for ImmunoTherapy of Cancer.

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft.

R. Vij, K. Trinkaus, P. Westervelt, 2017, Blood.

Evaluation of biochemical changes during in vivo erythrocyte senescence in the dog.

J. A. Gimm, P. Low, N. Mohandas, 1999, Blood.

CXCR4 and mobilization of hematopoietic precursors.

J. Dipersio, P. Ramírez, B. Nervi, 2009, Methods in enzymology.

An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Bing Wang, Samuel Achilefu, Christopher A. Miller, 2018, Leukemia.

Co-evolution of tumor and immune cells during progression of multiple myeloma

Joshua F. McMichael, Jared S. Fowles, Matthew A. Wyczalkowski, 2021, Nature Communications.

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Julie L Prior, David Piwnica-Worms, T. Ley, 2009, Blood.

Targeting CXCR4 in AML and ALL

J. Dipersio, Daniel Cancilla, M. Rettig, 2020, Frontiers in Oncology.

Functional and epigenetic phenotypes of humans and mice with DNMT3A Overgrowth Syndrome

Christopher A. Miller, Harrison W. Gabel, T. Ley, 2021, Nature Communications.

Preclinical evaluation of Mab CC188 for ovarian cancer imaging

S. Achilefu, J. Dipersio, G. Sudlow, 2012, International journal of cancer.

Immune Escape of Relapsed AML Cells after Allogeneic Transplantation

Christopher A. Miller, R. Wilson, R. Fulton, 2018, The New England journal of medicine.

Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated.

R. Vij, K. Trinkaus, P. Westervelt, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

BoneGraft-versus-Leukemia after Allogeneic Engraftment , Graft-versus-Host Disease , and Gene-Expressing T Cells Affects Kinetics of In Vivo Elimination of Suicide

J. Haug, J. Dipersio, D. Piwnica-Worms, 2004 .

Gold Nanoclusters Doped with (64)Cu for CXCR4 Positron Emission Tomography Imaging of Breast Cancer and Metastasis.

J. Dipersio, K. Wooley, Yongfeng Zhao, 2016, ACS nano.

Phase-1/-2 study of pomalidomide in chronic GvHD

J. Dipersio, R. Gale, M. Rettig, 2016, Bone Marrow Transplantation.

Marrow Microenvironment and Biology of Mobilization of Stem Cells

J. Dipersio, M. Rettig, M. Schroeder, 2016 .

Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice

D. Griggs, J. Dipersio, Julie K. Ritchey, 2016 .

BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.

J. Dipersio, E. Deych, Julie K. Ritchey, 2009, Blood.

Antibody-drug conjugates targeting CD45 plus Janus kinase inhibitors effectively condition for allogeneic hematopoietic stem cell transplantation

J. Dipersio, Julie K. Ritchey, M. Rettig, 2020, bioRxiv.

Conditioning for Hematopoietic Stem Cell Transplantation Using Antibody-Drug Conjugate Targeting CD45 Permits Engraftment across Immunologic Barriers

J. Dipersio, M. Rettig, M. Cooper, 2018, Blood.

Mobilized peripheral blood: an updated perspective

J. Dipersio, M. Rettig, D. Karpova, 2019, F1000Research.

Get Outta Here! Addition of Mobilizing Agents to Conditioning Regimen Improves Donor Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation for Wiskott-Aldrich Syndrome.

M. Rettig, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity

F. Gao, J. Dipersio, R. Jayasinghe, 2022, Nature Communications.

Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4

J. Dipersio, G. Ansstas, M. Rettig, 2012, Leukemia.

Flotetuzumab and other T-Cell Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells.

J. Dipersio, E. Chendamarai, R. Jayasinghe, 2022, Blood.

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.

T. Yau, S. Rutella, J. Dipersio, 2020, Blood advances.

Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia

M. Minden, S. Rutella, J. Dipersio, 2019, Science Translational Medicine.

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

S. Rutella, J. Dipersio, J. Wigginton, 2018, Blood.

Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs®)

J. Dipersio, P. Moore, Julie K. Ritchey, 2013 .

Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma

S. Achilefu, J. Dipersio, Julie K. Ritchey, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

C. Viero, J. Dipersio, J. Wigginton, 2018, Blood.

Application of CXCR4 Inhibitors in Leukemia

J. Dipersio, G. Ansstas, M. Rettig, 2012 .

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

S. Rutella, J. Dipersio, M. Jongen‐Lavrencic, 2020 .

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

B. Fox, J. Dipersio, P. Moore, 2017 .

Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.

G. Uy, A. Cashen, M. Rettig, 2008, Expert opinion on biological therapy.

Machine learning–based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors

F. Gao, J. Dipersio, G. Uy, 2021, Blood advances.

Targeting VLA 4 integrin and CXCR 2 mobilizes serially repopulating hematopoietic stem cells

A. Trumpp, D. Griggs, F. Gao, 2019 .

Preferential Mobilization of CD34+ Plasmacytoid Dendritic Cell Precursors by Plerixafor.

J. Dipersio, E. Deych, Julie K. Ritchey, 2009 .

Characterization of Human CD34+ Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor

W. Shannon, J. Dipersio, Julie K. Ritchey, 2008 .

Rapid Mobilization of Long Term Repopulating Hematopoietic Stem Cells (HSC) with AMD15057, a Small Molecule Inhibitor of VLA4; Synergism with AMD3100 and G-CSF

J. Dipersio, Julie K. Ritchey, P. Ramírez, 2008 .

BIO 5192 , a small molecule inhibitor of VLA-4 , mobilizes hematopoietic stem and progenitor cells

J. Dipersio, E. Deych, Julie K. Ritchey, 2009 .

AMD3100 Mobilizes Acute Promyelocytic Leukemia Cells from the Bone Marrow into the Peripheral Blood and Sensitizes Leukemia Cells to Chemotherapy.

T. Ley, J. Dipersio, G. Bridger, 2005 .

A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.

R. Vij, P. Westervelt, J. Dipersio, 2016, Clinical lymphoma, myeloma & leukemia.

Effect of pH on the self-association of erythrocyte band 3 in situ.

P. Low, C. Orendorff, M. Rettig, 2001, Biochimica et biophysica acta.

An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Christopher A. Miller, R. Fulton, S. Achilefu, 2018, Leukemia.

Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer

S. Achilefu, M. Tomasson, J. Dipersio, 2018, Nature Communications.

Kinetics of Human and Murine Mobilization of Acute Myeloid Leukemia in Response to AMD3100.

J. Dipersio, C. Abboud, P. Ramírez, 2007 .

In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET

S. Achilefu, J. Dipersio, N. Fettig, 2021, EJNMMI Research.

3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance

J. Dipersio, J. Griffin, A. Azab, 2021, Leukemia & lymphoma.

CiTE antibody for AML.

J. Dipersio, M. Rettig, 2018, Blood.

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

F. Gao, C. Hofmeister, R. Vij, 2022, Leukemia.

Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival

R. Vij, J. Dipersio, Julie K. Ritchey, 2022, Scientific reports.

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

F. Gao, P. Westervelt, J. Dipersio, 2021, Blood.

Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents

Walter J. Akers, Carolyn J. Anderson, Michael H. Tomasson, 2016, The Journal of Nuclear Medicine.

Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma

Samuel Achilefu, Duanwen Shen, Monica Shokeen, 2017, The Journal of Nuclear Medicine.

Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

Matthew A. Wyczalkowski, L. Yao, M. Wendl, 2023, Cancer research.

A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML.

R. Vij, S. Kulkarni, P. Westervelt, 2009 .

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

F. Gao, R. Vij, J. Dipersio, 2023, Nature Medicine.

Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide

J. Dipersio, M. Rettig, Zachary D. Crees, 2023, Therapeutic advances in hematology.

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product

Stephen M. Shaw, P. Westervelt, J. Dipersio, 2018, Blood.

[(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility.

R. Fulton, K. Cornetta, J. Dipersio, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.

R. Vij, S. Kulkarni, P. Westervelt, 2008 .

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

P. Westervelt, J. Dipersio, H. Kantarjian, 2018, Blood.

High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability

K. Trinkaus, P. Westervelt, J. Dipersio, 2012 .

Rapid and Prolonged Mobilization of Human CD34+ Hematopoietic Stem Cells Following Intravenous (IV) Administration of Plerixafor

J. Dipersio, M. Rettig, K. McFarland, 2010 .

Innovations in hematopoietic stem-cell mobilization: A review of Innovations in hematopoietic stem-cell mobilization: A review of the novel CXCR4 inhibitor motixafortide the novel CXCR4 inhibitor motixafortide

J. Dipersio, M. Rettig, Zachary D. Crees, 2022 .

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

P. Riedell, R. Vij, P. Westervelt, 2017 .

Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma

P. Westervelt, J. Dipersio, N. Bartlett, 2020 .

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies

J. Dipersio, R. Turk, Julie K. Ritchey, 2023, Leukemia.

Gold Nanoclusters Doped with (64)Cu for CXCR4 Positron Emission Tomography Imaging of Breast Cancer and Metastasis.

J. Dipersio, K. Wooley, Yongfeng Zhao, 2016, ACS nano.

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.

R. Vij, P. Westervelt, D. Link, 2008, Blood.

68Ga-Galmydar: A PET imaging tracer for noninvasive detection of Doxorubicin-induced cardiotoxicity

R. Laforest, A. Salter, Monica Sharma, 2019, PloS one.

Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.

F. Gao, J. Dipersio, P. Moore, 2016, Blood.

Clinical Trials and Observations

Chieh-Yu Liu, K. Trinkaus, P. Westervelt, 2022 .

Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial

J. Dipersio, E. Dubberke, Julie K. Ritchey, 2023, Open forum infectious diseases.

The tetraspanin CD53 protects stressed hematopoietic stem cells via promotion of DREAM complex–mediated quiescence

Qian Dong, C. Luke, M. Rettig, 2022, Blood.

Blinatumomab consolidation post-autologous stem cell Blinatumomab consolidation post-autologous stem cell transplantation in patients with diffuse large B-cell lymphoma transplantation in patients with diffuse large B-cell lymphoma

P. Westervelt, J. Dipersio, Julie K. Ritchey, 2022 .

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

P. Westervelt, J. Dipersio, Julie K. Ritchey, 2023, Blood.

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma

A. Laganà, S. Lonial, M. Dhodapkar, 2024, bioRxiv.

A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)

J. Dipersio, J. Wigginton, R. Lechleider, 2014, Journal of Immunotherapy for Cancer.

Streptavidin-drug conjugates streamline optimization of antibody-based conditioning for hematopoietic stem cell transplantation

J. Dipersio, E. Chendamarai, Julie K. Ritchey, 2024, bioRxiv.

Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc

F. Gao, J. Dipersio, Julie K. Ritchey, 2023, Blood advances.

Development of VLA4 and CXCR4 Antagonists for the Mobilization of Hematopoietic Stem and Progenitor Cells

J. Dipersio, M. Rettig, Peter G Ruminski, 2024, Biomolecules.

Forced Expression of the “IY” Mutant Inosine Monophosphate Dehydrogenase II Results in Physiologically Significant Resistance to Mycophenolic Acid In Vitro.

J. Dipersio, M. Rettig, M. Schroeder, 2006 .